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Abstract
A proportion of breast cancers are attributable to BRCA1 or BRCA2 mutations. Technological advances has meant that muta-
tion testing in newly diagnosed cancer patients can be used to inform treatment plans. Although oncologists increasingly 
deliver treatment-focused genetic testing (TFGT) as part of mainstream ovarian cancer care, we know little about non-genetics 
specialists’ views about offering genetic testing to newly diagnosed breast cancer patients. This study sought to determine 
genetics and non-genetics specialists’ views of a proposal to mainstream BRCA1 and 2 testing in newly diagnosed breast 
cancer patients. Qualitative interview study. Nineteen healthcare professionals currently responsible for offering TFGT in 
a standard (triage + referral) pathway (breast surgeons + clinical genetics team) and oncologists preparing to offer TFGT 
to breast cancer patients in a mainstreamed pathway participated in in-depth interviews. Genetics and non-genetics profes-
sionals’ perceptions of mainstreaming are influenced by their views of: their clinical roles and responsibilities, the impact 
of TFGT on their workload and the patient pathway and the perceived relevance of genetic testing for patient care in the 
short-term. Perceived barriers to mainstreaming may be overcome by: more effective communication between specialities, 
clearer guidelines/patient pathways and the recruitment of mainstreaming champions.
Keywords BRCA1 and BRCA2 treatment focussed testing · Mainstreaming · Clinician perspectives · Qualitative analysis
Introduction
The contribution of BRCA1 and BRCA2 mutations to the 
incidence of breast and ovarian cancer has been acknowl-
edged for a number of years [1, 2]. Cumulative lifetime 
risks (until age 80 years) of breast cancer associated with 
BRCA1/BRCA2 mutations are estimated to be as high as 
72% (65–79%) and 69% (61–77%), respectively, while 
ovarian cancer risks are 44% (36–53%) and 17% (11–25%) 
[3]. Patients with breast cancer who have a germline 
BRCA1/BRCA2 mutation are at increased risk of ipsilateral 
[4] and contralateral tumours compared with those present-
ing with sporadic disease [3]. Genetic testing of cancer 
patients and their unaffected relatives facilitates the imple-
mentation of risk-reducing strategies including: enhanced 
surveillance, chemoprevention and risk-reducing surgery 
(bilateral mastectomy and/or bilateral salphingo-oophorec-
tomy) [5].
Recent technological advances in sequencing, decreasing 
costs and the development of new treatments, for example, 
poly(ADP-ribose) polymerase inhibitors (PARPi), mean that 
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now BRCA testing can be used to inform cancer treatment 
plans [6]. Knowledge of BRCA mutation status of breast 
cancer patients can inform the extent of breast surgery 
and the appropriateness of adjuvant radiotherapy for those 
considering risk-reducing mastectomy and (neo-)adjuvant 
chemotherapy regimen [7–9]. Ovarian cancer patients are 
now selected for treatment with the PARPi olaparib based 
on their BRCA mutation status and their response to first line 
therapies [6, 10].
Despite the fact that BRCA testing has been available 
for over two decades, diagnostic testing has been limited to 
women with a strong family history, plus specific tumour 
characteristics, and it is only more recently that treatment 
focussed BRCA genetic testing (TFGT) has become more 
widely available for newly diagnosed cancer patients, 
leading to the possibility of mainstreaming this service in 
oncology.
Mainstreaming genetics/genomics
Mainstreaming, namely, the implementation of genetic/
genomic testing in other specialities, for example, oncol-
ogy, to aid diagnosis and/or treatment, offers the promise of 
streamlined pathways and tailored treatment for individual 
patients [11, 12]. A number of challenges to the implementa-
tion of mainstreamed genetic services in the UK have been 
identified, including: a lack of consistency in services and 
patient management including the interpretation of genetic 
variants, the educational requirements of non-genetics spe-
cialists who may be required to offer testing, a lack of fund-
ing and human resources within clinical genetics to support 
mainstream services plus a lack of pre-existing information, 
guidelines or protocols [13, 14]. Despite these challenges, 
there is evidence that mainstreaming of BRCA1 and 2 testing 
in gynaecological-oncology clinics in both the UK and Aus-
tralia has been successfully implemented [15–17]. However, 
there is a lack of data on the impact of mainstreaming of 
BRCA testing in breast clinics.
A recent study suggests approximately a third of newly 
diagnosed breast cancer patients in the US are not offered 
BRCA1/BRCA2 genetic tests, despite the fact that the result 
may inform their treatment [18]. This may be due to the fact 
that testing for BRCA2/BRCA1 mutations is perceived as 
more informative for prevention than determining treatment 
options in breast cancer [19], although recent research on 
the BRCA1/BRCA2 mutation carriers’ response to carbopl-
atin therapy [9] suggest this perception may change. Indeed, 
earlier Australian studies have suggested that healthcare 
professionals (oncologists, breast surgeons and breast care 
nurses) do regard BRCA testing as potentially valuable in the 
management of breast cancer as well as having a positive 
impact on risk management decisions, with the majority of 
respondents suggesting this service should be mainstreamed 
[20, 21].
It is therefore, more likely that the failure to implement 
TFGT in mainstream breast cancer care results from the 
existence of a knowledge or skills gap. A recent US study 
found that breast surgeons, particularly those who see fewer 
patients, report they lack confidence to discuss BRCA1 and 
BRCA2 testing with patients [22]. A UK based study simi-
larly suggests that non-genetics specialists (breast surgeons, 
medical and clinical oncologists) question their ability to 
correctly interpret genetics reports, although the breast 
surgeons in this study rated themselves as more confident 
about interpreting reported genetic variants than the medi-
cal oncologists [23]. One of the problems of many of these 
studies is that the health professionals involved had little, if 
no, experience of offering TFGT. To address this issue we 
undertook a study of UK genetics and non-genetics health-
care professionals’ perceptions of the delivery of TFGT. 
This paper describes their views of a proposal to mainstream 
this service in either the breast or oncology clinic at the 
study site.
Methods
TFGT at the study site
This study was based in a tertiary referral centre that offers 
TFGT to newly diagnosed patients with ovarian or breast 
cancer. When the study began patients with ovarian cancer 
were offered, and consented for TFGT by their gynaecolog-
ical-oncologists in a mainstreamed pathway, while newly 
diagnosed breast cancer patients were triaged by breast 
surgeons and referred to clinical genetics for TFGT (see 
Fig. 1). Triage of breast cancer patients considered a com-
bination of factors: age at diagnosis (< 40 years), tumour 
type (triple negative) plus a family history of disease. The 
multidisciplinary team meeting (MDM) confirmed onward 
referral following discussion of individual cases. TFGT was 
implemented at three different points in the breast care path-
way depending on disease presentation, either: prior to any 
treatment (Pathway 1), following neoadjuvant chemotherapy 
(Pathway 2) or following conservative breast surgery (Path-
way 3). In all cases, decision-making about risk-reducing 
mastectomy took into account BRCA mutation results. In 
addition to taking consent for TFGT, the clinical genet-
ics team disclosed results and discussed the personal and 
familial risk implications with those identified as carrying a 
pathogenic mutation or Variant of Uncertain Significance, 
and initiated a familial cascade, if appropriate.
During this study it was decided that TFGT should be 
mainstreamed in the breast cancer pathway and the clini-
cal genetics team began discussions with the surgical and 
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medical oncology teams to decide who would assume 
responsibility for offering and consenting breast cancer 
patients for genetic testing, with a view to piloting a main-
streamed service during the summer of 2018 (see “Results” 
section). As indicated in Fig. 1, while the clinical genetics 
team were prepared to outsource offering and consenting 
patients for genetic testing to streamline patient care, they 
proposed to retain responsibility for results disclosure (to 
patients and breast cancer specialists), genetic counselling 
and familial cascading.
Recruitment, data collection and analysis
All staff responsible for discussing and/or (potentially) offer-
ing TFGT in the breast, oncology and genetics clinics at the 
study site were emailed a recruitment pack (invitation letter, 
study information sheet and expression of interest form). In 
addition, SW described the study to clinicians attending the 
breast cancer MDMs.
Qualitative data were collected during in-depth 
face–face interviews; these were informed by a topic 
guide and digitally recorded. Interviews focused on: staff 
experiences and views of TFGT and its role in clinical 
practice, perceptions of mainstreaming of genetic testing 
and ethical implications of TFGT. Interviews took place in 
the hospital and lasted 19–77 min. Digital audio files were 
transcribed verbatim. SW and NH independently reviewed 
and coded interview transcripts using NVivo11 software 
(QSR International Pty Ltd., 2015). Codes and larger 
themes were inductively and deductively determined from 
the interviews and literature, respectively [24]. Below we 
report on two themes in the analysis Staff perceptions 
of mainstreaming and Moving genetic testing into the 
mainstream.
Results
Twenty-two of the 31 eligible staff members involved in 
(potentially) offering TFGT at the study site accepted the 
invitation, including: 7/12 Breast surgeons (58%), 6/10 
medical oncologists (60%) and 6/7 (86%) members of the 
clinical genetics team. Twenty-one interviews were under-
taken between February 2017 and January 2018, only data 
collected in interviews with the 19 staff members (clini-
cal genetics, oncology and surgical teams) involved in the 
care of breast cancer patients are reported here. The data 
suggest that staff views of mainstreaming were influenced 
by perceptions of: their role responsibilities, its workload 
implications and the perceived relevance of TFGT for their 
practice.
Fig. 1  Current and proposed 
breast cancer care pathways at 
study site. Shaded area indicates 
tasks undertaken by clinical 
genetics team
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Genetics team’s perceptions of mainstreaming
The clinical genetics team (see Table 1) described their pri-
mary role as facilitating individuals and families to make 
decisions about their genetic risks and risk management. 
Bearing this in mind, the introduction of TFGT in breast 
cancer care at the study site has had a major impact on the 
clinical genetics team. Team members said that the introduc-
tion of TFGT had increased their workload and that they had 
put on extra clinics to consent newly diagnosed patients for 
TFGT. They worried that having a referral to clinical genet-
ics for TFGT at the point of diagnosis could be anxiety-pro-
voking for patients. Consequently, with the aim of improving 
patient care, the team had agreed to invite the surgical team 
and the medical oncologists at the study site to consider 
taking on the task of offering TFGT and consenting their 
patients. Team members observed that this potential change 
in service provision would not only be in patients’ interest, 
but also would allow them to concentrate on offering genetic 
counselling and familial cascading to the smaller group of 
patients identified as carrying a pathogenic mutation. Thus, 
as far as the genetics team were concerned, mainstreaming 
TFGT would streamline the patient pathway and provide 
better patient care by ensuring that only those patients who 
need genetic services would receive them.
Surgical team’s perceptions of mainstreaming
Most members of the surgical team said they were happy 
with the role they currently play in TFGT, namely triaging 
patients for referral to clinical genetics, and were not keen 
to implement a mainstreamed service in the breast clinic. 
First, they said they lacked the requisite expertise to counsel 
patients about genetic testing (see Table 2). Many interview-
ees reflected that a surgeon’s primary responsibility is to 
treat patients and “get the cancer out” as quickly as possible, 
not to talk to women about genetics. Second, surgical team 
members commented that they had neither the time nor the 
capacity to take on another task. Many talked about their 
unsustainable workload and a couple drew explicit compari-
sons with the genetics clinic, which they suggested had a 
much smaller patient list than the breast clinic.
Finally, from the surgical team’s perspective, TFGT 
is not regarded as having much relevance for treatment 
decision-making. While they acknowledged that in some 
cases a woman’s mutation status will inform the extent of 
her surgery, or the way it is performed, in most instances 
TFGT, which many characterised as revealing future risks, 
is perceived as clashing with surgical priorities (Table 2 e.g. 
S1). As far as the surgeons where concerned, treating actual 
disease has priority over risk management or disease preven-
tion. Indeed, some talked about the potential difficulties of 
fitting TFGT into the timeline dictated by the UK’s NHS 
treatment targets.
Oncologists’ perceptions of mainstreaming
In contrast to the surgical team, the medical oncologists 
responded positively to their proposed involvement in main-
streaming. Offering TFGT and consenting newly diagnosed 
Table 1  The clinical genetics team’s perceptions of TFGT
Role responsibility: Facilitating individual and familial decision-making
In genetics we’re like acutely aware of families and, other people who are at risk, the implications of your test for your family CG5
…if testing is done through, say for the breast patients through the breast unit by the breast clinicians, the genetics services then only have to 
engage with those with an underlying genetic condition, so perhaps genetics services could be more focused on the patients that need that 
service. CG3
Redesigning the care pathway: Providing the best service
As professionals we have to look at the best service for the patients, whether it’s having genetic discussion and testing at the point of diagnosis 
or whether they are referred on to our service, that’s obviously the most important thing. I think as professionals we have the skills to pick up 
someone coming along with a positive gene test and take them on their journey rather than starting their journey with them pre-test…I think 
the things to take into consideration are sort of speed, if speed is what people want, and also the practicalities, take into consideration the 
practicalities of the lady who has maybe a distance to travel from the hospital she’s been diagnosed at, if she then has to return to that hospital 
two days later for another consultation you could perhaps take that into consideration, the literal practicalities of the genetic testing…. CG2
Patients are getting referred at the point of diagnosis, and it’s meant that we’ve had clinics put aside on a weekly basis that are for patients 
who’ve just got a diagnosis, …. usually the patient just needs half an hour for that consultation CG1
Relevance for practice: Less relevant for clinical genetics practice
if it’s being done for treatment implications it’s therefore a diagnostic test. And it perhaps shouldn’t be considered any differently from any other 
diagnostic test that you would do if there are true treatment implications for that person. GC3
I think there’s an assumption that treatment is going to become a bigger and bigger thing, that we’re seeing the start of treatment being influ-
enced by genotype, so in a way it’s partly, it’s a good place to start, isn’t it. I think that women are also, there’s stuff out there sort of suggest-
ing that it might change their treatment, and if you were going through breast cancer you might think, oh actually I need to know that. It’s 
come out of trying to do genetic counselling in a woman that’s just been diagnosed with breast cancer and how the counselling model doesn’t 
fit so well with somebody that’s got all that other stuff going on and it actually sits neater in the oncology model. CG4
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patients did not concern the oncologists who reported feel-
ing confident that, given their current role and responsibili-
ties, they had more than enough expertise to take on this 
task. Indeed, many reflected that they currently have to pre-
sent and explain a range of different types of complex treat-
ment and prognostic information to patients and families and 
therefore, explaining the risks and uncertainties of genetic 
testing would not be particularly challenging (Table 3).
This group rarely pointed to their workload as a barrier 
to taking on the responsibility for offering and consenting 
patients for TFGT, indeed, like the clinical genetics team, 
they regarded mainstreaming in oncology as enabling them 
to offer breast cancer patients streamlined or expedited care. 
Finally, the oncologists regarded TFGT as having a great 
deal of relevance for their practice. They described genetic 
testing as allowing them to stratify their patients to ensure 
that individuals receive the most effective treatment. Thus, 
in contrast to the surgical team, this group saw TFGT as 
potentially facilitating their practice not constraining it.
In summary, the data suggest that different groups of 
healthcare providers perceive TFGT differently and sug-
gest there are a number of barriers to the implementation 
Table 2  The surgical team’s perceptions of TFGT
Role responsibility: Treating cancer
We’re there to diagnose their lumps and treat them. But in the middle of the thing we’re being asked to do all this stuff TFGT as well. And I think 
that’s becoming pretty difficult to do. ‘Cause we’re mainly interested if you come with a lump. You want to know what your lump is. We’d want 
to do all the investigations that day, work out what it is. And that’s what the focus is. S2
The genetics team wanted us to do all this this rapid testing. It’s because they’re overwhelmed, they just want to get us to spend the time talking 
to the patients about it. Yeah of course we want more patients assessed than we used to, for obvious reasons, but we don’t have the time or 
skills to counsel people about gene testing. We wouldn’t dream of asking a geneticist to counsel people about breast surgery S6
Redesigning the care pathway: Mainstreaming TFGT will increase workload beyond capacity
When you looked at the numbers it mainstreaming was going to add up to hundreds of hours a year that we just don’t have time or staff to do. 
Which is exactly why they genetics wanted us to do it, because they don’t have the time or staff to do it either S5
We had about 35 patients in our clinic this morning between two people. In my afternoon follow-up clinic I’ve got 14, 16 patients coming 
between two and half-four or something, so you cannot stop for 40 min to have a chat with somebody about consenting for gene testing on top 
of everything else you’re doing. S3
Relevance for practice: TFGT less relevant for surgical practice
Quite often we feel that the priority is treating the cancer. So we could do a smaller surgical procedure to deal with the cancer initially. The 
patient could then have chemotherapy if appropriate. And then if the genetic testing showed that they carried a mutation, then we could con-
sider more radical surgery later on. S1
It’s the cancer, treating the cancer should be the first priority. Because when you know that the patient’s BRCA, surgically what you are doing is 
prevention, not treatment. So the first thing is to treat the cancer, the prevention of the secondary cancer, prevention of recurrence can be done, 
and then what you try to achieve is the best cosmetic result. S4
Table 3  Oncology team’s views of TFGT
Role responsibility: Diagnosing and treating cancer
It’s no different to any other diagnostic test that we’d do really. We’re all fairly used to going through the process of consenting and counselling 
patients for diagnostic tests in a whole range of settings so it’s, I mean obviously clinical genetics is perhaps a bit more complex than some of 
the other tests, but by no means the most complex testing that we do. O5
I mean, you know, they’re seeing an oncologist to have oncology treatment, if we think it’s relevant to have BRCA testing, yes there is the issue 
of the implications for the rest of the family, but there’s direct implication for that patient’s management and we direct all the other things we 
need to know about that patient in order to direct their management so it seems odd to me for this one particular thing we have to refer them 
on to somewhere else and wait for them to be seen and all the rest of it. So it seems to me simpler just to do it in the context of the bit of the 
service or the bit of the pathway where the patient is being seen and where it’s directly relevant. O4
Redesigning the care pathway: Mainstreaming TFGT will streamline care
I think it will just speed up the testing process a bit because there’ll not be a, you know, there was a short delay while we had to wait for the 
clinical geneticist to see the patient, whereas now because they’re going straight to the test in our clinic that’ll just cut out that short delay. O5
The advantages of mainstreaming in oncology? I guess particularly just having control of that pathway and the results coming to me, I think it 
would just save time. O6
Relevance for practice: TFGT informs oncology practice
When we find a BRCA-positive patient it makes a significant difference to what we do, adding platinum, post-treatment post-surgical trial 
options at the moment. These come and go of course, and then obviously massive difference to the surgery. O3
So I will be seeking BRCA status in somebody who has got a breast cancer. Very different from somebody who’s at risk, primarily it’s because 
it will change their treatment, basically women with a BRCA 1, BRCA 2 germline mutation who have a breast cancer, their response rate to 
carboplatin is quite high, it’s higher than many other drugs. O4
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of mainstreamed genetic services in some specialities. The 
following section outlines a number of ways in which these 
barriers might be overcome  (see Table 4 below).
Moving genetic testing into the mainstream
First, successful mainstreaming of genetics/genomics may 
depend upon the degree of inter-professional communica-
tion that exists at individual sites. Many of our interviewees 
commented that the layout of their hospital and the makeup 
of the MDMs at the study site, which the genetics team did 
not attend, meant that there was little contact between the 
different teams and this was perceived as impeding commu-
nication about mainstreaming. Members of the surgical and 
clinical genetics teams said they rarely met and did not know 
each other well, if at all, which may explain why members 
of the surgical team appeared to have unrealistic expecta-
tions of what they would be asked to do in a mainstreamed 
service, with a number suggesting they would be required to 
provide genetic counselling (e.g. S6, Table 2). Others sug-
gested that communication about mainstreaming should be 
on-going between and within teams.
Beyond establishing effective communication about 
mainstreaming, it was observed that handing over TFGT to 
non-genetics specialists could be facilitated by the recruit-
ment of mainstreaming champions, individuals from the 
target specialty who advocate for the implementation of 
genetic testing. The genetics team observed that the ovar-
ian pathway at the study site had been mainstreamed a 
few years previously primarily because the gynaecologi-
cal oncologists had lobbied for its implementation. They 
observed that a couple of the oncologists were promoting 
TFGT in the oncology clinic and thus, champions were 
emerging in the breast cancer pathway. Finally, a number 
of interviewees commented that effective implementation 
of mainstreaming could be facilitated by comprehensive 
guidelines detailing how patients should be managed. 
These would not only define the patient pathway, but also 
could be used to justify or reinforce particular patient man-
agement decisions.
Table 4  Moving genetic testing into the mainstream
Maintain communication
I think the genetics services and the cancer services, I think we need a more cohesive approach, we need a better understanding of what each of 
us is thinking. CG3
We have quite a lot of informal, I mean mostly with name in clinical genetics team quite a lot of informal positive contact. But no, we live in 
slightly different worlds. Which is a shame O4
[I would like to] have an opportunity to sit down with the people who do that discussion now and make sure that my amateur version of it is 
covering the same ground…. I could do with like a little chat from the genetics service folk and maybe refreshers or an ongoing conversation 
from time to time to make sure we don’t diverge our approach as the service develops’. O3
I think mainstreaming could happen very quickly, it just requires us as a group of oncologists to sit down and have that other conversation. We 
don’t meet all of us terribly often because half of them do clinics outside so there aren’t many days a week when all of us, are actually here.…
We have meetings about every three months and there always seem to be more pressing, urgent issues to resolve. I guess we just need to put 
it on the agenda for the next one. It’s just, it’s getting everybody in the room and agreeing, and having the conversation and people being 
comfortable. O4
Identify speciality champions
If someone is in a department, you know, in renal or something and they’ve got a particular interest in genetics then it makes a massive differ-
ence CG5
You need champions. I think all mainstreaming you need a champion in the mainstream specialty that wants to work with you, because only 
they really know how it fits with their way of working, their colleagues. We don’t know, we think we know what they want, and we have asked 
them, we keep asking them, we haven’t just invented it in a vacuum. I think you need to be in the specialty to understand the psychology of the 
specialty, really. And that’s strange. You know, our best, our best links with other specialties are when we’ve got a champion. CG4
Develop clear guidance
Work on any pathway, particularly something that’s probably got variable input is quite good to try and set it out clearly, particularly from the 
patient’s point of view, the patient expectation, so if you set out a clear pathway the patient then trundles along quite gently and quietly and 
knows what’s going on and you get less anxiety and less uncertainty and therefore less questioning and therefore less time taken up by the 
professional. If the pathway is well set out and well organized, I think generally you get less fall out from it which you as the consultant have to 
pick up. And I think from our point of view it’s better if there is a well set up pathway because then all the right people go into that pathway. So 
the more you know about, as a professional about the pathway and how it’s set out the better you use it basically. And if it’s a well thought out, 
well set up pathway then the patients will get the best out of it without causing more work. O1
I know they produce guidelines of what people we’ll refer,.. but I’ve been onto them clinical genetics team about this a number of times, that we 
lack very good genetic tools. There are some online assessment tools. But sometimes we could do, you know, there are apps for everything. We 
need better apps for genetic testing. You know, identifying which patients should be genetically tested. S2
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Discussion
This study suggests that non-genetics specialists involved 
in the provision of TFGT to newly diagnosed breast can-
cer patients have contrasting views about the mainstream-
ing of this service. These relate specifically to their per-
ceptions of the roles and responsibilities related to their 
speciality—what a surgeon/oncologist does or should be 
normally expected to do—whether offering genetic testing 
would negatively or positively impact their workload and 
lastly, the perceived relevance of genetic information for 
patient care.
In contrast to earlier studies that suggest breast surgeons 
would be best placed to offer TFGT to newly diagnosed 
patients [20, 21] the breast surgeons we interviewed sum-
marily dismissed this suggestion, citing a lack of expertise 
in providing genetic counselling and support for patients 
making this decision. The discrepancy between these find-
ings may arise from the fact that, with the exception of one 
study [21] that involved non-genetics professionals who 
had previously offered TFGT during an RCT, this earlier 
research has involved healthcare professionals who were 
considering a hypothetical service. Arguably, our obser-
vations are better supported by a recent US study [22] of 
breast surgeons potentially responsible for offering TFGT 
and consenting patients, which found that that over two-
thirds regularly refer patients on for genetic counselling 
and testing, citing a lack of confidence about discussing 
the individual and familial implications of genetic testing 
with patients.
The implementation of genetic/genomic testing in main-
stream specialities has implications for workload man-
agement, and all three groups in this study discussed the 
impact of (potentially) offering TFGT on their workload 
[13, 14]. The surgical team suggested that they do not 
have the capacity to discuss TFGT with newly diagnosed 
patients, reinforcing earlier research, which found that 
over 40% of non-genetics professionals said that provid-
ing TFGT took more time and increased their workload 
[21] and reflects the findings of a recent systematic review, 
which suggests lack of consultation time is seen as a major 
barrier to incorporating genetics into primary care [25]. 
In contrast, the clinical genetics team and oncologists we 
interviewed supported mainstreaming commenting that 
this would simplify the patient pathway and expedite 
treatment decisions, similar views were expressed by non 
genetics professionals in Douma et al.’s study [21], with 
90% perceiving the rapid turnaround time for test results 
as a major advantage of TFGT.
Finally, the perceived relevance of genetics/genom-
ics for practice was an important influence on interview-
ees’ responses. Oncologists emphasised the utility of 
establishing patients’ BRCA status for treatment, provid-
ing further confirmation that mainstreaming is widely 
accepted in oncology [6, 15–17]. In contrast, the surgical 
team regarded TFGT as having little relevance for patient 
care in the short-term, constructing BRCA testing as pri-
marily important for secondary prevention in the medium 
term [19]. The surgical team’s prioritisation of treatment 
rather than prevention may be influenced by the 16 week 
treatment targets issued by the Department of Health in 
the UK, which may have the effect of focussing this group 
on short-term goals. Similar observations were recorded 
in an evaluation of genetics pilots in the UK [26], which 
found that primary care practitioners were more concerned 
about meeting pre-existing governmental targets than 
introducing genetic services. The idea that non-genetics 
healthcare professionals may struggle to see the relevance 
of genetics for their practice has been observed in ear-
lier studies, which suggested that General Practitioners’ 
ambivalence about the integration of genetics in primary 
care was linked to their lack of knowledge about genetics 
and their uncertainty about the relevance of genetic testing 
for patient management in primary care [25–27].
Finally, these interviewees pointed to a number of issues 
that may facilitate the implementation of genetic testing in 
the mainstream: more effective communication, particularly 
across specialities, identification of mainstreaming champi-
ons and more comprehensive guidelines/educational support 
for those in mainstream specialities [28, 29]. These sugges-
tions confirm earlier observations made by those involved in 
piloting mainstreamed services in the UK [14] and Australia 
[21], and reflect earlier experiences at the study site.
Limitations
This research has a number of limitations. First, data col-
lection was limited to one site, thus restricting the study’s 
generalizability. Despite this, the findings confirm those gen-
erated in consultations [13] and questionnaire studies [20], 
which have ascertained hypothetical views about TFGT and 
mainstreaming. Second the data captured staff views about 
mainstreaming prior to the implementation of the service 
only; arguably a longitudinal evaluation of the implementa-
tion of mainstreamed services would have enabled us not 
only to identify potential barriers, but also to determine how 
these were overcome. We suggest that such an evaluation 
should be the focus of future research.
Conclusions
If genetic/genomic testing is to be implemented in main-
stream specialties, then we need to think strategically 
about where, and how to introduce this service and, more 
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importantly, who will introduce it? With regard to the latter 
question, different specialists may have clear ideas about 
whether they have the expertise or capacity to provide this 
service and its relevance for their practice and these may 
thwart attempts at implementation. Mainstreaming may have 
the potential to streamline cancer care, but it can only do so 
if non-geneticists who work in the mainstream can see its 
potential, and this may be a challenge without further educa-
tion of the healthcare workforce.
Acknowledgements We would like to thank staff who facilitated 
recruitment and/or participated in the interviews and/or multidiscipli-
nary meetings, Chris McKevitt, Caroline Pearce and Emma Goettke 
for reading suggestions and Julia Lawton for her support throughout 
the lifetime of the project.
Authors contributions NH designed the study analysed the data 
authored the article, SW collected and analysed the data, commented 
on the article, DS, MP, CG and OY designed the study and commented 
on the paper.
Funding We are grateful to Breast Cancer Now for their support 
(2016MayPR700).
Compliance with ethical standards 
Conflict of interest SW, MP, DS, JL, OY, and NH declare that they 
have no conflict of interest. CG has sat on Advisory Boards for As-
traZeneca, Clovis and Tesaro, has received lecture fees and research 
funding from AstraZeneca and Tesaro.
Ethical approval The study was approved by the University of Edin-
burgh Research Ethics Committee, The Quality Improvement Team and 
the Caldicott Guardian at the Western General Hospital, Edinburgh. All 
interviewees gave their consent for publication of their interview data.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Claus EB, Schildkraut JM, Thompson WD et  al (1996) The 
genetic attributable risk of breast and ovarian cancer. Cancer 
77:2318–2324
 2. Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and 
BRCA2 mutations among 1,342 unselected patients with invasive 
ovarian cancer. Gynecol Oncol 121:353–357
 3. Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of 
breast, ovarian, and contralateral breast cancer for BRCA1 and 
BRCA2 mutation carriers. JAMA 317:2402–2416
 4. Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of con-
servatively managed early-onset breast cancer by BRCA1/2 status. 
Lancet 359:1471–1477
 5. National Institute for Health and Clinical Excellence (2013) 
Familial breast cancer: classification, care and managing breast 
cancer and related risks in people with a family history of breast 
cancer. NICE guideline [CG164]. National Institute for Health and 
Clinical Excellence
 6. George A, Kaye S, Banerjee S (2017) Delivering widespread 
BRCA testing and PARP inhibition to patients with ovarian can-
cer. Nat Rev Clin Oncol 14:284–296
 7. Weitzel JN, McCaffrey SM, Nedelcu R et al. Effect of genetic 
cancer risk assessment on surgical decisions at breast cancer diag-
nosis. Arch Surg. https ://doi.org/10.1001/archs urg.138.12.1323
 8. Telli ML, Jensen KC, Vinayak S, et a (2015) Phase II study of 
gemcitabine, carboplatin, and imiparib as neoadjuvant therapy 
for triple-negative and BRCA1/2 mutation-associated breast 
cancer with assessment of a tumor-based measure of genomic 
instability: PrECOG 0105. J Clin Oncol 33:1895–1901
 9. Tutt A, Tovey H, Cheang MCU et al. Carboplatin in BRCA1/2-
mutated and triple-negative breast cancer BRCAness sub-
groups: the TNT Trial. Nat Med. https ://doi.org/10.1038/s4159 
1-018-0009-7
 10. Rafii S, Gourley C, Kumar R et al (2017) Baseline clinical pre-
dictors of antitumor response to the PARP inhibitor olaparib 
in germline BRCA1/2 mutated patients with advanced ovarian 
cancer. Oncotarget. https ://doi.org/10.18632 /oncot arget .17005 
 11. Davies SC (2017) Annual report of the Chief Medical Officer 
2016, generation genome. Department of Health, London
 12. Independent Cancer Taskforce (2015) Achieving world-class 
cancer outcomes a strategy for England 2015–2020
 13. Slade I, Riddell D, Turnbull C et al. Development of cancer 
genetic services in the UK: a national consultation. Genome 
Med. https ://doi.org/10.1186/s1307 3-015-0128-4
 14. Bennett CL, Burke SE, Burton H et al. A toolkit for incorporat-
ing genetics into mainstream medical services: learning from 
service development pilots in England. BMC Health Serv Res. 
https ://doi.org/10.1186/1472-6963-10-125
 15. Percival N, George A, Gyertson J et al. The integration of BRCA 
testing into oncology clinics. Br J Nurs. https ://doi.org/10.12968 
/bjon.2016.25.12.690
 16. Kentwell M, Dow E, Antill Y et al (2017) Mainstreaming can-
cer genetics: a model integrating germline BRCA testing into 
routine ovarian cancer clinics. Gynecol Oncol 145:130–136
 17. Rahman B, Lanceley A, Kristeleit RS et  al. Mainstreamed 
genetic testing for women with ovarian cancer: first-year expe-
rience. J Med Genet. https ://doi.org/10.1136/jmedg enet-2017-
10514 0
 18. Katz SJ, Ward KC, Hamilton AS et al. Gaps in receipt of clinically 
indicated genetic counselling after diagnosis of breast cancer. J 
Clin Oncol. https ://doi.org/10.1200/JCO.2017.76.2369
 19. Katz SJ, Kurian AW, Morrow M. Treatment decision making 
and genetic testing for breast cancer: mainstreaming mutations. 
JAMA. https ://doi.org/10.1001/jama.2015.8088
 20. Burcher S, Meiser B, Mitchell G Oncology health profession-
als’ attitudes toward treatment-focused genetic testing for women 
newly diagnosed with breast cancer. Personal Med. https ://doi.
org/10.2217/pme.13.45
 21. Douma KFL, Meiser B, Kirk J et al. Health professionals’ evalu-
ation of delivering treatment-focused genetic testing to women 
newly diagnosed with breast cancer. Fam Cancer. https ://doi.
org/10.1007/s1068 9-014-9770-z
 22. Kurian AW, Li Y, Hamilton AS et al. Gaps in incorporating 
germline genetic testing into treatment decision-making for 
early-stage breast cancer. J Clin Oncol. https ://doi.org/10.1200/
JCO.2016.71.6480
 23. Eccles BK, Copson E, Maishman T et al. Understanding of BRCA 
VUS genetic results by breast cancer specialists. BMC Cancer. 
https ://doi.org/10.1186/s1288 5-015-1934-1
 24. Maxwell JA (2012) Qualitative research design: an interactive 
approach, vol 41. Sage Publications, London
Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed…
1 3
 25. Mikat-Stevens NA, Larson IA, Tarini BA (2015) Primary-care 
providers’ perceived barriers to integration of genetics services: 
a systematic review of the literature. Genet Med 17:169–176
 26. Martin G, Currie G, Finn RJ, Health Services Research Policy. 
Bringing genetics into primary care: findings from a national 
evaluation of pilots in England. J Health Serv Res Policy. https ://
doi.org/10.1258/jhsrp .2009.00815 8
 27. Robins R, Metcalfe S (2004) Integrating genetics as practices of 
primary care. Soc Sci Med 59:223–233
 28. Scheuner MT, Hamilton AB, Peredo J et al. A cancer genetics 
toolkit improves access to genetic services through documentation 
and use of the family history by primary-care clinicians. Genet 
Med. https ://doi.org/10.1038/gim.2013.75
 29. Sperber NR, Carpenter JR, Cavallari LH et al. Challenges and 
strategies for implementing genomic services in diverse settings: 
experiences from the Implementing GeNomics In pracTicE 
(IGNITE) network. BMC Med Genomics. https ://doi.org/10.1186/
s1292 0-017-0273-2
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
